1. Home
  2. MDWD vs VPV Comparison

MDWD vs VPV Comparison

Compare MDWD & VPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • VPV
  • Stock Information
  • Founded
  • MDWD 2000
  • VPV 1993
  • Country
  • MDWD Israel
  • VPV United States
  • Employees
  • MDWD N/A
  • VPV N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • VPV Trusts Except Educational Religious and Charitable
  • Sector
  • MDWD Health Care
  • VPV Finance
  • Exchange
  • MDWD Nasdaq
  • VPV Nasdaq
  • Market Cap
  • MDWD 184.8M
  • VPV 184.0M
  • IPO Year
  • MDWD 2014
  • VPV N/A
  • Fundamental
  • Price
  • MDWD $19.45
  • VPV $10.34
  • Analyst Decision
  • MDWD Strong Buy
  • VPV
  • Analyst Count
  • MDWD 1
  • VPV 0
  • Target Price
  • MDWD $25.00
  • VPV N/A
  • AVG Volume (30 Days)
  • MDWD 78.0K
  • VPV 36.6K
  • Earning Date
  • MDWD 03-20-2025
  • VPV 01-01-0001
  • Dividend Yield
  • MDWD N/A
  • VPV 3.60%
  • EPS Growth
  • MDWD N/A
  • VPV N/A
  • EPS
  • MDWD N/A
  • VPV N/A
  • Revenue
  • MDWD $19,720,000.00
  • VPV N/A
  • Revenue This Year
  • MDWD $10.15
  • VPV N/A
  • Revenue Next Year
  • MDWD $25.62
  • VPV N/A
  • P/E Ratio
  • MDWD N/A
  • VPV N/A
  • Revenue Growth
  • MDWD N/A
  • VPV N/A
  • 52 Week Low
  • MDWD $11.04
  • VPV $8.58
  • 52 Week High
  • MDWD $24.00
  • VPV $10.28
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 55.03
  • VPV 46.44
  • Support Level
  • MDWD $19.59
  • VPV $10.12
  • Resistance Level
  • MDWD $20.62
  • VPV $10.40
  • Average True Range (ATR)
  • MDWD 0.83
  • VPV 0.07
  • MACD
  • MDWD 0.02
  • VPV 0.04
  • Stochastic Oscillator
  • MDWD 54.60
  • VPV 71.43

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About VPV Invesco Pennsylvania Value Municipal Income Trust (DE)

Invesco Pennsylvania Value Municipal Income Trust is a diversified, closed-end management investment company. The investment objective is to provide common shareholders with a high level of current income exempt from federal and Pennsylvania income taxes and, where possible under local law, local income and personal property taxes, consistent with preservation of capital.

Share on Social Networks: